Clinical correlative analyses from CheckMate cohorts (009/10/025) showed that among the 50 master TFs, high BARX2 expression significantly correlated with improved overall survival in the entire cohort of patients with ccRCC (Supplementary Data 13 and Supplementary Fig. S6E) and in the subgroup treated with the anti-PD1, nivolumab (Supplementary Data 13 and Supplementary Fig. S6F). The gene discussed is BARX2; the disease is nonpapillary renal cell carcinoma.